

Development of a new thiol site-specific prosthetic group and its conjugation with [cys⁴⁰]-exendin-4 for in vivo targeting of insulinomas

Xuyi Yue, Dale O. Kiesewetter, Jinxia Guo, Zhongchan Sun, Xiaoxiang Zhang, Lei Zhu, Gang Niu, Ying Ma, Lixin Lang, Xiaoyuan Chen*

National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), 31 Center Drive, Bethesda, Maryland 20892, United States

Supporting Information

Mouse serum stability study




Figure S1. Stability studies of [¹⁸F]FPenM-[cys⁴⁰]-exendin-4 incubated with mouse serum at 0, 0.5, and 2.5 h, respectively.

Metabolite analysis




Figure S2. Metabolite analysis by reversed-phase HPLC for tumor, kidney and urine samples after [^{18}F]FPenM-[cys 40]-exendin-4 (100 μCi) injection.